Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome

Related Experiment Video

Updated: Aug 15, 2026

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
08:56

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Published on: May 17, 2018

Jo Nijs1, Kenny De Meirleir

  • 1Department of Human Physiology, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium. Jo.Nijs@vub.ac.be

In Vivo (Athens, Greece)
|November 10, 2005
PubMed

Insights

Chronic Fatigue Syndrome (CFS) patients show an up-regulated and deregulated 2'–5' oligoadenylate (2-5 A) synthetase/RNase L pathway, impacting NK-cell function and apoptosis. Further research into treating this pathway impairment in CFS is needed.

Area of Science:

  • Immunology
  • Molecular Biology
  • Virology

Background:

  • The 2'-5' oligoadenylate (2-5 A) synthetase/RNase L pathway is crucial in antiviral responses and cellular regulation.
  • Dysregulation of this pathway has been implicated in various chronic diseases, including Chronic Fatigue Syndrome (CFS).

Purpose of the Study:

  • To review and synthesize the existing evidence on the specific impairments of the 2-5 A synthetase/RNase L pathway in CFS.
  • To explore the functional consequences and clinical relevance of these pathway alterations in CFS patients.

Main Methods:

  • Review of published literature and existing evidence on the 2-5 A synthetase/RNase L pathway in CFS.
  • Analysis of molecular and functional data related to pathway components, NK-cell function, and apoptosis in CFS.

Main Results:

  • CFS patients exhibit an up-regulated and deregulated 2-5 A synthetase/RNase L pathway.
  • Key findings include increased bioactive 2-5A synthetase, elevated RNase L activity, and specific proteolysis of RNase L.
  • Pathway deregulation correlates with decreased Natural Killer (NK) cell function and altered apoptotic processes in CFS.

Conclusions:

  • The 2-5 A synthetase/RNase L pathway is significantly impaired in CFS patients, presenting as both up-regulated and deregulated.
  • These impairments are linked to reduced immune function and apoptosis abnormalities, suggesting clinical relevance.
  • Targeted studies investigating therapeutic interventions for the deregulated 2-5 A synthetase/RNase L pathway in CFS are warranted.

More Related Videos

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse09:25

The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse

Published on: May 31, 2016

Related Concept Videos

Muscle Recovery and Fatigue01:24

Muscle Recovery and Fatigue

Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective response...
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased ATP...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
ATP Synthase: Structure01:18

ATP Synthase: Structure

ATP synthase or ATPase is among the most conserved proteins found in bacteria, mammals, and plants. This enzyme can catalyze a forward reaction in response to the electrochemical gradient, producing ATP from ADP and inorganic phosphate. ATP synthase can also work in a reverse direction by hydrolyzing ATP and generating an electrochemical gradient. Different forms of ATP synthases have evolved special features to meet the specific demands of the cell. Based on their specific feature, ATP...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...